Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system

Microbes Infect. 2020 Nov-Dec;22(10):515-524. doi: 10.1016/j.micinf.2020.09.004. Epub 2020 Sep 19.

Abstract

This article discusses standard and new disruptive strategies in the race to develop an anti-COVID-19 vaccine. We also included new bioinformatic data from our group mapping immunodominant epitopes and structural analysis of the spike protein. Another innovative approach reviewed here is the use of BCG vaccine as priming strategy and/or delivery system expressing SARS-CoV-2 antigens.

Keywords: BCG; COVID-19; RBD domain; SARS-CoV-2; Vaccines.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2 / chemistry
  • Antibodies, Viral / immunology
  • BCG Vaccine / administration & dosage*
  • COVID-19 / immunology*
  • COVID-19 / prevention & control
  • COVID-19 Vaccines / immunology*
  • Epitope Mapping
  • Humans
  • Middle East Respiratory Syndrome Coronavirus / chemistry
  • Protein Binding
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / chemistry
  • Spike Glycoprotein, Coronavirus / immunology*
  • Vaccines, DNA / immunology*
  • Viral Vaccines / immunology*

Substances

  • Antibodies, Viral
  • BCG Vaccine
  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • Vaccines, DNA
  • Viral Vaccines
  • spike glycoprotein, SARS-CoV
  • spike protein, SARS-CoV-2
  • Angiotensin-Converting Enzyme 2